Atezolizumab for the treatment of non-small cell lung cancer
- 27 July 2017
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 10 (9) , 935-945
Abstract
Introduction: The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high neoantigen creation and sensitization to immune recognition. Atezolizumab was the first approved antibody that targets the PD-1 ligand (PD-L1). Areas covered: This drug profile article covers the basics of the cancer-immunity cycle and reviews some aspects of innate and adaptive immunology. We discuss the discovery of PD-L1 and PD-L2 while highlight the potential differences in targeting PD-L1 versus PD-1. In addition, we briefly summarized the available pre-clinical and clinical data of atezolizumab use in NSCLC. A special section covers the challenges of PD-L1 immunohistochemistry assay. Expert commentary: PD-1:PD-L1 blockade has taken the lead in the immunotherapeutics field and represents the backbone of developing combination immunotherapies. Atezolizumab represents a step forward in the treatment of advanced NSCLC, nonetheless PD1:PD-L1 blockade in early-stage lung cancer is still a matter of debate.Keywords
Funding Information
- National Cancer Institute (P30 CA008748)
This publication has 60 references indexed in Scilit:
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionJournal of Immunology Research, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphomaBlood, 2010
- B7-H1–Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy ResponsesThe Journal of Immunology, 2010
- PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directionsMucosal Immunology, 2009
- PD‐1 signaling in primary T cellsImmunological Reviews, 2009
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cellsBlood, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- T-cell regulation by CD28 and CTLA-4Nature Reviews Immunology, 2001
- The Hallmarks of CancerCell, 2000